These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19654540)

  • 1. Gastroduodenal mucosal defense.
    Nayeb-Hashemi H; Kaunitz JD
    Curr Opin Gastroenterol; 2009 Nov; 25(6):537-43. PubMed ID: 19654540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroduodenal mucosal defense.
    deFoneska A; Kaunitz JD
    Curr Opin Gastroenterol; 2010 Nov; 26(6):604-10. PubMed ID: 20948371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroduodenal mucosal defense.
    Ham M; Kaunitz JD
    Curr Opin Gastroenterol; 2008 Nov; 24(6):665-73. PubMed ID: 19122513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury.
    Iijima K; Shimosegawa T
    World J Gastroenterol; 2015 Jul; 21(25):7709-17. PubMed ID: 26167071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury.
    Giral A; Ozdogan O; Celikel CA; Tozun N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2004 Jul; 19(7):773-7. PubMed ID: 15209624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroduodenal defense.
    Ham M; Kaunitz JD
    Curr Opin Gastroenterol; 2007 Nov; 23(6):607-16. PubMed ID: 17906436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulated regulatory T cell function is associated with increased peptic ulcer in Helicobacter pylori-infection.
    Bagheri N; Shirzad H; Elahi S; Azadegan-Dehkordi F; Rahimian G; Shafigh M; Rashidii R; Sarafnejad A; Rafieian-Kopaei M; Faridani R; Tahmasbi K; Kheiri S; Razavi A
    Microb Pathog; 2017 Sep; 110():165-175. PubMed ID: 28666843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by aspirin but not indomethacin.
    Slomiany BL; Piotrowski J; Slomiany A
    J Endotoxin Res; 2001; 7(3):203-9. PubMed ID: 11581571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etiopathogenetic principles and peptic ulcer disease classification.
    Tytgat GN
    Dig Dis; 2011; 29(5):454-8. PubMed ID: 22095009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals.
    Brzozowski T; Konturek PC; Sliwowski Z; Kwiecień S; Drozdowicz D; Pawlik M; Mach K; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():67-79. PubMed ID: 17033106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stomach and duodenum.
    Schubert ML
    Curr Opin Gastroenterol; 2009 Nov; 25(6):527-8. PubMed ID: 19786871
    [No Abstract]   [Full Text] [Related]  

  • 12. Nonsteroidal antiinflammatory drug-induced mucosal lesions of the upper gastrointestinal tract and their relationship to Helicobacter pylori.
    Rybár I; Masaryk P; Mateicka F; Kopecký S; Rovenský J
    Int J Clin Pharmacol Res; 2001; 21(3-4):119-25. PubMed ID: 12067141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses.
    Robinson K; Kenefeck R; Pidgeon EL; Shakib S; Patel S; Polson RJ; Zaitoun AM; Atherton JC
    Gut; 2008 Oct; 57(10):1375-85. PubMed ID: 18467372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helicobacter pylori eradication may reduce the risk of gastroduodenal lesions in chronic NSAID users.
    Russell RI
    Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):465-9. PubMed ID: 9494858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds.
    Scarpignato C; Pelosini I
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of NSAID-related gastroduodenal mucosal injury.
    Aalykke C; Lauritsen K
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):705-22. PubMed ID: 11566036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptic ulcer disease in Helicobacter pylori-infected children: clinical findings and mucosal immune response.
    Hernández C; Serrano C; Einisman H; Villagrán A; Peña A; Duarte I; Torres J; Riera F; Harris PR
    J Pediatr Gastroenterol Nutr; 2014 Dec; 59(6):773-8. PubMed ID: 25050847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-steroidal anti-inflammatory drug-induced gastroduodenal toxicity and Helicobacter pylori.
    Wardi J; Shirin H
    Isr Med Assoc J; 2003 Mar; 5(3):195-7. PubMed ID: 12725142
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs.
    Quan C; Talley NJ
    Am J Gastroenterol; 2002 Dec; 97(12):2950-61. PubMed ID: 12492176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of non-steroidal anti-inflammatory drugs on gastric and duodenal prostaglandin concentrations in patients with Helicobacter pylori infection.
    Tseng GY; Lin HJ; Lin HY; Perng CL; Lee FY; Lo WC; Tsay SH; Li AS; Chang FY; Lee SD
    Hepatogastroenterology; 1999; 46(26):1000-4. PubMed ID: 10370655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.